Kidney Cancer

$91,166P30FY2015CANIH

Dana-Farber Cancer Inst, Boston MA

Investigators

Linked publications, trials & patents

Paper 39713466 Paper 39666914 Paper 39605676 Paper 39593217 Paper 39536083 Paper 39532885 Paper 39484503 Paper 39389170 Paper 39322760 Paper 39168126 Paper 39160372 Paper 39107288 Paper 39042477 Paper 39025073 Paper 39024561 Paper 38996877 Paper 38992034 Paper 38979326 Paper 38979245 Paper 38942046 Paper 38924531 Paper 38889153 Paper 38861327 Paper 38815709 Trial NCT03029325 Trial NCT02627430 Trial NCT02142803 Trial NCT02097225 Trial NCT02079740 Trial NCT01940809 Trial NCT01835184 Trial NCT01822509 Trial NCT01575522 Trial NCT01434316 Trial NCT01307631 Trial NCT01283035 Trial NCT01116648 Trial NCT01026324 Trial NCT00956163 Trial NCT00888134 Trial NCT00662506 Trial NCT00622401 Trial NCT00458978 Trial NCT00458549 Trial NCT00429910 Trial NCT00400946 Trial NCT00376480 Trial NCT00357500 Trial NCT00301093 Trial NCT00126672 Trial NCT00101075 Trial NCT00098865 Trial NCT00098514 Trial NCT00096291 Trial NCT00095927 Trial NCT00095901 Trial NCT00095875 Trial NCT00095836 Trial NCT00090857 Trial NCT00084838 Trial NCT00083031 Trial NCT00079326 Trial NCT00072436 Trial NCT00069940 Trial NCT00053976 Trial NCT00052611 Trial NCT00047294 Trial NCT00047281 Trial NCT00020670 Trial NCT00020605 Trial NCT00007917 Trial NCT00006107 Trial NCT00005988 Trial NCT00005096 Trial NCT00004180 Trial NCT00004163 Trial NCT00004070 Trial NCT00003761 Trial NCT00003744 Trial NCT00003657 Trial NCT00003200 Trial NCT00003058 Trial NCT00003045 Patent 9512485 Patent 7786269 Patent 7396678 Patent 7229755 Patent 7048929 Patent 6908617 Patent 6479284 Patent 6479281 Patent 5861424 Patent 5670530 Patent 5618831 Patent 5502214 Patent 5360803 Patent 4625014 Patent 4618492 Patent 4542225 Patent 4035566

Abstract

The Kidney Cancer Program seeks to conduct innovative basic research into the molecular and biological basis for various cancers of the kidney with the goals of identifying: 1) meaningful biomarkers for eariy detection, prognosis and treatment selection; 2) novel factors associated with either innate or acquired resistance to existing therapies that could be targets for future therapeutic development; and 3) new therapeutic targets. In addition, the Program seeks to conduct cutting-edge clinical trials across all disease strata in the hopes of identifying more effective treatments, used either alone or in combination, and better ways of predicting who should receive each therapy. It also aims to better understand the factors contribufing to kidney cancer development and the relative cost effectiveness of various diagnosfic and treatment approaches. Finally, the Kidney Cancer Program will to continue to educate, train and promote the career advancement of the next generation of kidney cancer investigators. The Program has five Specific Aims: 1. idenfify and validate novel targets for renal cell carcinoma (RCC) and other cancers of the kidney 2. Identify biomarkers for eariy detection, prognosis and treatment selection 3. Identity mechanisms for and opportunities for overcoming resistance to existing RCC therapies 4. Explore novel immunotherapies, either alone of in combination, in patients with advanced RCC 5. Investigate the epidemiology of RCC and cost effectiveness of treatment for this disease. The Program was first approved and funded by the NCI CCSG in 2005, at which fime it received a score of Excellent to Outstanding merit. The Program has 36 members from six DF/HCC institutions, seven departments of HMS and one department of HSPH. In 2009, total peer-review funding totaled $3.8 million (total costs), of which $3 million was from the NCI. During the project period (2006 to 2010), members published 371 papers, of which 15% were intra-programmafic , 41% were inter-programmatic and 27% were inter-institufional.

View original record on NIH RePORTER →